Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BeOne Medicines

Explore full profile

Innovative oncology therapeutics for global cancer care accessibility, formerly BeiGene

Dongcheng District, ChinaFounded 2010Biotech & Life Sciences
Valuation $32B Market cap · 2026
Revenue $6.51B Latest reported FY
EBITDA $1.01B Latest reported FY

At a glance

Founded
2010
Headquarters
Dongcheng District, China
Listing
IPO 2016
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Latest news

Press, funding announcements and product moves mentioning BeOne Medicines.

See all news

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later1 investor entered at this stage

  • Rock Springs Capital
Employees mapped 3,529 incl. 11 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
41 countries with
team presence
🇨🇳 China36.1%
🇺🇸 United States31.9%
🇦🇺 Australia6%
🇨🇭 Switzerland4.5%
🇫🇷 France2.4%
Top 5 of 41 shown
Web traffic by country
53K monthly visits
across markets
🇺🇸 United States39.8%
🇬🇧 United Kingdom14.9%
🏳️ Korea6.4%
🏳️ Republic of5.5%
🇮🇳 India3.4%
Top 5 markets shown

Patents

Estimated portfolio value
$228M

433 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where BeOne Medicines was the backer or acquirer, 2021–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

5 deals across BeOne Medicines's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where BeOne Medicines deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        BeOne Medicines's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        5 of 5 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about BeOne Medicines on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See BeOne Medicines on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.